[BidClub_]

SHOW DIRECTORY

Sourcery

Molly O'Shea interviews leading investors, CEOs, and founders about technology companies, markets, and company building.

SOURCE DESCRIPTION · RSS

41 EPISODESENTRACKED SHOW
SUBSCRIBE[Feed_]
26 episodes1 active
Language
SourceryEN · 60 min

Ex-Twitter CEO Says We’re Underestimating AI Agents by 10,000x

Parag AgrawalMolly O'Shea

Agrawal estimates agent web use at 10–20% of human levels, implying substantial runway if his 1,000x thesis holds.Parallel plans around 10X growth, but capacity hinges on GPU type, location and deployment within five milliseconds of its index.Higher-signal search is said to halve searches and cut tokens; model-priced publisher payments could help keep agent access open.

SourceryEN · 56 min

Apollo’s Yahoo Playbook, 5 Years After the $5B Deal

Jim LanzoneMolly O'Shea

Lanzone says Apollo has largely recovered its $4.8 billion Yahoo cost through early cash returns and disposals including AOL.The reset shut loss-making ad tech that cost hundreds of millions annually and opened inventory to competing demand, while retaining DSP.Scout restores owned search, but Lanzone makes no IPO commitment and hesitates to call Yahoo’s audience distribution a moat.

SourceryEN · 89 min

Vercel CEO Guillermo Rauch on Building the Internet for Agents

Guillermo RauchMolly O'Shea

Vercel added 1.5 billion deployments in 10 months after taking roughly 10 years to reach 1 billion, while agentic deployments rose from 3% to 60%.Rauch sees cheap personalized code pressuring SaaS interfaces and lifting deployment infrastructure value, but retention, sustainable economics, and agent security remain unresolved as autonomy expands.

SourceryEN · 70 min

Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX

Molly O'SheaNworah Ayogu

Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.

SourceryEN · 55 min

Perplexity CEO: SMBs Could Drive the Next Economic Boom

Molly O'SheaAravind Srinivas

AI-native SMBs could become a larger source of US GDP growth through greater capital and headcount efficiency.Revenue is up 5X year over year, while a reported one-person customer spends more than $1 million annually and makes $3 million through automation, supporting a recursive-usage thesis.The open question is whether hybrid local-cloud agents can make privacy, sovereignty, and long-context economics durable advantages without sacrificing feedback loops or frontier capability.

SourceryEN · 85 min

USV’s New $900M Fund: Fred Wilson, Rebecca Kaden & Mike Mignano

Fred WilsonRebecca KadenMichael MignanoMolly O'Shea

USV’s $900 million fund targets 30-40 companies with $10 million-$30 million Series A checks as larger rounds and scaling costs reshape venture.Its AI thesis spans applications, infrastructure, physical AI, and energy, while usage retention, compute costs, inference subsidies, distribution, interoperability, trust, and leadership concentration remain key tests.

SourceryEN · 28 min

If an AI Model Can Cheat, It Will | Turing CEO on Reward Hacking

Molly O'SheaJohn Collison

AI training is shifting from benchmark scores to economically valuable work, making high-fidelity environments for real workflows, tools, data, and verifiers a bottleneck.Enterprises may gain an edge by owning evaluations and correction data around differentiating workflows while routing tasks across models for accuracy, cost, and latency.Reward hacking and limited agent endurance make permissions, auditability, and verification key adoption constraints.

SourceryEN · 58 min

Annie Lamont: $14B Managed, 70+ Exits, 15 IPOs, 7x Midas Investor

Jonathan SiddharthMolly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.

SourceryEN · 62 min

We’re Reaching the Physical Limits of Chips

Molly O'SheaAnnie Lamont

AI’s investable bottlenecks are shifting toward power, memory, cooling, and data transfer as Moore’s Law nears a physical plateau.Micron, SK hynix, and Samsung control 95% of memory, whose price rose 700% this year as hyperscalers absorbed supply.Photonics could relieve several constraints, with co-packaged optics expected beside GPUs within five years as memory pressure pushes specialized hardware beyond ever-larger models.

SourceryEN · 47 min

10 of The Wildest Hot Takes From the All-In Summit 2026

Molly O'SheaBrad GerstnerNaveen RaoJonathan NemanToby RiceWen SangGeoff WooNick ShirleyJake PaulKent DraperMichael Brandt

AI safety is converging toward company-led controls plus independent peer review, with Elon suggesting China might participate.Unconventional AI’s planned nanojoule-per-image disclosures could extend scaling and disrupt intelligence pricing, while Rao says software may capture very little value in 20 years.U.S. gas demand may rise 20–40%, and AIRIN’s 2026 capacity is sold out; data-center opposition and uncertain neocloud margins remain risks.